Clinical outcomes associated with ertapenem use in hypoalbuminemia: a retrospective cohort study

PURPOSE: Evaluate the clinical response to ertapenem for the treatment of bloodstream infection in patients with hypoalbuminemia compared to normoalbuminemia. METHODS: This retrospective chart review included adults with gram-negative bloodstream infections (GN-BSI) who received ertapenem and had a serum albumin level during their index hospitalization between January 2020 and May 2025. The primary outcome was a composite of 30-day mortality, bloodstream infection recurrence between 7 and 30 days from the index culture, clinical failure from day 3 of ertapenem until discharge or end of therapy (whichever came first), and 30-day readmission. RESULTS: A total of 273 patients met inclusion criteria - 146 with hypoalbuminemia (serum albumin < 2.5 g/dL) and 127 with normal levels (≥ 2.5 g/dL). Demographics were similar between cohorts, though ICU admission was more common in the hypoalbuminemia group and infection source varied between groups. The hypoalbuminemia group experienced higher rates of the composite (71.2% vs 47.2%, p < 0.001), 30-day mortality (20.6% vs 7.1%, p = 0.0016), and clinical failure (67.8% vs 45.7%, p < 0.0002). Rates of 30-day readmission and recurrence of index infection were low (∼2%) and did not differ significantly between groups. Multivariable logistic regression identified increased odds of the composite endpoint associated with hypoalbuminemia, steroid use, and higher Pitt bacteremia scores . CONCLUSION: In adults receiving ertapenem to treat susceptible GN-BSI, hypoalbuminemia was associated with increased odds of the composite outcome, 30-day mortality, and clinical failure. Larger prospective studies are needed to confirm these findings.

Authors

Institutions

Publication Details

Journal
American Journal of Health-System Pharmacy
Published
2026-11-20
DOI
https://doi.org/10.1093/ajhp/zxag410
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical outcomes associated with ertapenem use in hypoalbuminemia: a retrospective cohort study

Jimmy Gonzalez, Allison Kang, Sarah Valiante, Andy Hui et al.
5 links
American Journal of Health-System Pharmacy
Antibiotics Pharmacokinetics and Efficacy
article

Clinical outcomes associated with ertapenem use in hypoalbuminemia: a retrospective cohort study

Jimmy Gonzalez, Allison Kang, Sarah Valiante, Andy Hui, Antoinette Acbo
article en

Abstract

PURPOSE: Evaluate the clinical response to ertapenem for the treatment of bloodstream infection in patients with hypoalbuminemia compared to normoalbuminemia. METHODS: This retrospective chart review included adults with gram-negative bloodstream infections (GN-BSI) who received ertapenem and had a serum albumin level during their index hospitalization between January 2020 and May 2025. The primary outcome was a composite of 30-day mortality, bloodstream infection recurrence between 7 and 30 days from the index culture, clinical failure from day 3 of ertapenem until discharge or end of therapy (whichever came first), and 30-day readmission. RESULTS: A total of 273 patients met inclusion criteria - 146 with hypoalbuminemia (serum albumin < 2.5 g/dL) and 127 with normal levels (≥ 2.5 g/dL). Demographics were similar between cohorts, though ICU admission was more common in the hypoalbuminemia group and infection source varied between groups. The hypoalbuminemia group experienced higher rates of the composite (71.2% vs 47.2%, p < 0.001), 30-day mortality (20.6% vs 7.1%, p = 0.0016), and clinical failure (67.8% vs 45.7%, p < 0.0002). Rates of 30-day readmission and recurrence of index infection were low (∼2%) and did not differ significantly between groups. Multivariable logistic regression identified increased odds of the composite endpoint associated with hypoalbuminemia, steroid use, and higher Pitt bacteremia scores . CONCLUSION: In adults receiving ertapenem to treat susceptible GN-BSI, hypoalbuminemia was associated with increased odds of the composite outcome, 30-day mortality, and clinical failure. Larger prospective studies are needed to confirm these findings.

American Journal of Health-System Pharmacy
Rutgers, The State University of New Jersey (US), Jersey Shore University Medical Center (US)
Good health and well-being
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Clinical outcomes associated with ertapenem use in hypoalbuminemia: a retrospective cohort study — Jimmy Gonzalez, Allison Kang, et al. · American Journal of Health-System Pharmacy (2026) | TGRS Research Map | TGRS